Oasmia Pharmaceutical : Erik Penser Cancer Day Presentation

ERIK PENSER CANCER DAY

F.R. Martelet, M.D., CEO

7th October 2020

1

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

2

Oasmia - an innovation-focused specialty pharmaceutical company

Founded in 1999

Based in Uppsala, Sweden 26* employees

XR-17™ technology platform

Allowing micelle formulations of APIs, to be soluble in water

A growing pipeline, focused on Oncology but with potential in other therapeutic areas

NASDAQ Stockholm 2010 Market Cap approx. SEK 2,0 B

R&D-focused Production

Facility in Uppsala, Sweden

New Leadership

since March 2020

3	*By end of Q1 2021

The new team leading Oasmia's transformation

FRANCOIS MARTELET, M.D., Master's

Degree Business

Chief Executive Officer

Previous experience:

CEO in Biotechnology/ BioPharma in UK, DNK, US and senior executive global roles at Novartis Oncology, Merck & Co., Inc with large P&L responsibility

ANDERS HÄRFSTRAND, M.D., PhD.

Non-executive Chairman

Previous experience: Experienced

Pharma BoD, M&A experience, former executive positions in Pfizer, Pharmacia.

Pharmacia & Upjohn

FREDRIK JÄRRSTEN*

Chief Finance Officer

REINHARD KOENIG, M.D.

Acting Chief Medical

Officer

HEGE HELLSTRÖM,

B.A.

Board Member

PETER ZONABEND,

LL.M, EMLE

Board Member

ELIN TRAMPE,

Chief Technical

Officer

PETER SELIN*

Chief Business

Officer

BIRGIT STATTIN

NORINDER, MSc.

Board Member

4 *Start date TBC